Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $74.8 million.

  • Revolution Medicines' Accounts Payables rose 20605.58% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year increase of 20605.58%. This contributed to the annual value of $54.4 million for FY2024, which is 1191.33% down from last year.
  • Per Revolution Medicines' latest filing, its Accounts Payables stood at $74.8 million for Q3 2025, which was up 20605.58% from $56.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Accounts Payables ranged from a high of $74.8 million in Q3 2025 and a low of $9.6 million during Q1 2021
  • Moreover, its 5-year median value for Accounts Payables was $24.5 million (2024), whereas its average is $30.5 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 1745.37% in 2024, then soared by 20605.58% in 2025.
  • Quarter analysis of 5 years shows Revolution Medicines' Accounts Payables stood at $14.1 million in 2021, then surged by 51.57% to $21.3 million in 2022, then surged by 190.0% to $61.8 million in 2023, then dropped by 11.91% to $54.4 million in 2024, then soared by 37.52% to $74.8 million in 2025.
  • Its last three reported values are $74.8 million in Q3 2025, $56.8 million for Q2 2025, and $47.5 million during Q1 2025.